PAMAM dendrimers as delivery agents for antisense oligonucleotides

Pharmaceutical Research

Volumn 16, Issue 12, 1999, Pages 1799-1804

  Yoo, Hoon ^a   Sazani, Peter ^a   Juliano, R L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antisense; Dendrimers; Drug delivery; Luciferase; Splicing

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DENDRIMER; POLYAMIDOAMINE DENDRIMER; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; HELA CELL; HUMAN; HUMAN CELL; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RNA SPLICING;

EID: 0033404268     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018926605871     Document Type: Article

References (40)

1. R. L. Juliano, S. Alahari, H. Yoo, R. Kole, and M. Cho. Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides. Pharm. Res. 16:494-502 (1999).
2. S. K. Alahari, R. DeLong, M. H. Fisher, N. M. Dean, P. Viliet, and R. L. Juliano. Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression. J. Pharmacol. Exp. Ther. 286:419-428 (1998).
3. C. F. Bennett, M. Y. Chiang, H. Chan, J. E. Shoemaker, and C. K. Mirabelli. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 41:1023-1033 (1992).
4. L. Chaloin, P. Vidal, P. Lory, J. Mery, N. Lautredou, G. Divita, and F. Heitz. Design of carrier peptide-oligonucleotide conjugates with rapid membrane translocation and nuclear localization properties. Biochem. Biophys. Res. Commun. 243:601-608 (1998).
5. S. B. Rajur, C. M. Roth, J. R. Morgan, and M. L. Yarmush. Covalent protein-oligonucleotide conjugates for efficient delivery of antisense molecules. Bioconjug. Chem. 8:935-940 (1997).
6. G. Degols, J. P. Leonetti, and B. Lebleu. Sequence-specific activity of antisense oligonucleotides conjugated to poly (L-lysine)carriers. Ann. NY Acad. Sci. 660:331-333 (1992).
7. J. A. Hughes, A. I. Aronsohn, A. V. Avrutskaya, and R. L. Juliano. Evaluation of adjuvants that enhance the effectiveness of antisense oligodeoxynucleotides. Pharm. Res. 13:404-410 (1996).
8. E. Liang and J. Hughes. Characterization of a pH-sensitive surfactant, dodecyl-2-(1′-imidazolyl) propionate (DIP), and preliminary studies in liposome mediated gene transfer. Biochim. Biophys. Acta 1369:39-50 (1998).
9. X. Gao and L. Huang. Cationic liposome-mediated gene transfer. Gene Ther 2:710-722 (1995).
10. M. C. De Oliveira, E. Fattal, P. Couvreur, P. Lesieur, C. Bourgaux, M. Ollivon, and C. Dubernet. pH-sensitive liposomes as a carrier for oligonucleotides: a physico-chemical study of the interaction between DOPE and a 15-mer oligonucleotide in quasi-anhydrous samples. Biochim. Biophys. Acta 1372:301-310 (1998).
11. A. Tari, M. Khodadadian, D. Ellerson, A. Deisseroth, and G. Lopez-Berestein. Liposomal delivery of oligodeoxynucleotides. Leuk. Lymphoma 21:93-97 (1996).
12. P. L. Feigner, Y. J. Tsai, L. Sukhu, C. J. Wheeler, M. Manthorpe, J. Marshall, and S. H. Cheng. Improved cationic lipid formulations for in vivo gene therapy. Ann. NY Acad. Sci. 772:126-139 (1995).
13. J. Zabner, A. J. Fasbender, T. Moninger, K. A. Poellinger, and M. J. Welsh. Cellular and molecular barriers to gene transfer by a cationic lipid. J. Biol. Chem. 270:18997-19007 (1995).
14. R. L. Juliano and S. Akhtar. Liposomes as a drug delivery system for antisense oligonucleotides. Antisense Drug Res. Dev. 2:165-176 (1992).
15. S. K. Alahari, N. M. Dean, M. H. Fisher, R. Delong, M. Manoharan, K. L. Tivel, and R. L. Juliano. Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5′ cholesterol-conjugated phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 50:808-919 (1996).
16. M. Berton, S. Sixou, R. Kravtzoff, C. Dartigues, L. Imbertie, C. Allal, and G. Favre. Improved oligonucleotide uptake and stability by a new drug carrier, the SupraMolecular Bio Vector (SMBV). Biochim. Biophys. Acta 1355:7-19 (1997).
17. Q. Zhao, J. Temsamani, and S. Agrawal. Use of cyclodextrin and its derivatives as carriers for oligonucleotide delivery. Antisense Drug Res. Dev. 5:185-192 (1995).
18. S. Abdou, J. Collomb, F. Sallas, A. Marsura, and C. Finance. β-Cyclodextrin derivatives as carriers to enhance the antiviral activity of an antisense oligonucleotide directed toward a coronavirus intergenic consensus sequence. Arch. Virol. 142:1585-1602 (1997).
19. J. G. Lewis, K. Y. Lin, A. Kothavale, W. M. Flanagan, M. D. Matteucci, R. B. DePrince, J. Mook RA, R. W. Hendren, and R. W. Wagner. A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc. Natl. Acad. Sci. USA 93:3176-3181 (1996).
20. O. Zelphati, L. S. Uyechi, L. G. Barron, and Jr. Szoka FC. Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells. Biochim. Biophys. Acta 1390:119-133 (1998).
21. M. Poznanski and R. L. Juliano. Biological approaches to the controlled delivery of drugs: a critical review. Pharmacol. Rev. 36:277-336 (1984).
22. E. Tomlinson. Theory and practice of site-specific drug delivery. Adv. Drug Del. 1:87-198 (1987).
23. Y. Takakura and M. Hashida. Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. Pharm. Res. 13:820-831 (1996).
24. M. J. Cho and R. Juliano, Macromolecular versus small-molecule therapeutics: drug discovery, development and clinical considerations. Trends Biotechnol. 14:153-158 (1996).
25. D. A. Tomalia, A. M. Naylor, and W. A. Goddard. Starburst dendrimers: molecular-level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter. Angew Chem. Int. E. Engl. 29:138-175 (1990).
26. A. Bielinska, J. F. Kukowska-Latallo, J. Johnson, D. A. Tomalia, and Jr. Baker JR. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res. 24:2176-2182 (1996).
27. R. Delong, K. Stephenson, T. Loftus, M. Fisher, S. Alahari, A. Nolting, and R. L. Juliano. Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery. J. Pharm. Sci. 86:762-764 (1997).
28. J. Haensler and Jr. Szoka FC. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture Bioconj. Chem. 4:372-379 (1993).
29. J. F. Kukowska-Latallo, A. U. Bielinska, J. Johnson, R. Spindler, D. A. Tomalia, and J. r. Baker JR. Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proc. Natl. Acad. Sci. USA 93:4897-4902 (1996).
30. L. Qin. D. R. Pahud, Y. Ding, A. U. Bielinska, J. F. Kukowska-Latallo, J. r, Baker JR, and J. S. Bromberg. Efficient transfer of genes into murine cardiac grafts by Starburst polyamidoamine dendrimers. Human Gene Ther. 9:553-560 (1998).
31. M. X. Tang, C. T. Redemann, and Jr. Szoka FC. In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconj. Chem. 7:703-714 (1996).
32. G. Hartmann, A. Krug, M. Bidlingmaier, U. Hacker, A. Eigler, R. Albrecht, C. J. Strasburger, and S. Endres. Spontaneous and cationic lipid-mediated uptake of antisense oligonucleotides in human monocytes and lymphocytes. J. Pharmacol. Exp. Ther. 285:920-928 (1998).
33. J. A. Hughes, A. V. Avrutskaya, K. L. Brouwer, E. Wickstrom, and R. L. Juliano. Radiolabeling of methylphosphonate and phosphorothioate oligonucleotides and evaluation of their transport in everted rat jejunum sacs. Pharm. Res. 12:817-824 (1995).
34. O. Zelphati and Jr. Szoka FC. Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Pharm. Res. 13:1367-1372 (1996).
35. O. Zelphati and Jr. Szoka FC. Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl. Acad. Sci. USA 93:11493-11498 (1996).
36. E. G. Marcusson, B. Bhat, M. Manoharan, C. F. Bennett, and N. M. Dean. Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus. Nucleic Acids Res. 26:2016-2023 (1998).
37. S. H. Kang, M. J. Cho, and R. Kole. Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development. Biochemistry 37:6235-6239 (1998).
38. H. Sierakowska, M. J. Sambade, S. Agrawal, and R. Kole. Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA 93:12840-12844 (1996).
39. J. Carmichael, W. G. DeGraff, A. F. Gazdar, J. D. Minna, and J. B. Mitchell. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res. 47:943-946 (1987).
40. R. K. DeLong, H. Yoo, S. K. Alahari, M. Fisher, S. M. Short, E. Zirbes, R. Kole, V. Janout, S. L. Regan, and R. L. Juliano. Novel cationic amphiphiles as delivery agents for antisense oligonucleotides. Nucleic Acids Res. 27:3334-3341 (1999).